Abbott’s buyout of Exact Sciences (EXAS) cashes out director’s shares

Rhea-AI Filing Summary

Exact Sciences director Shacey Petrovic reported disposing of all common stock holdings in connection with the closing of Exact Sciences’ merger with Abbott Laboratories. The Form 4 shows issuer dispositions of 16,406 and 5,398 directly held shares, plus 7,095 shares held indirectly in a grantor retained annuity trust.

According to the merger terms, at the effective time each share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, without interest. All restricted shares outstanding immediately before the merger became fully vested, were cancelled, and likewise converted into the cash merger consideration (less any applicable tax withholding).

Insights

M&A and corporate actions analyst

Director’s entire Exact Sciences stake was cashed out at $105 per share in Abbott’s acquisition.

The transactions reflect the mechanical cleanup of equity positions when Exact Sciences became a wholly owned subsidiary of Abbott Laboratories. All disclosed common shares, including those in a grantor retained annuity trust, were treated uniformly under the merger agreement.

The footnotes specify that each issued and outstanding share converted into the right to receive $105.00 in cash, and that unvested, restricted stock fully vested and received the same consideration, minus taxes. Future company disclosures from Abbott will frame how this acquired business contributes to its results.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Petrovic Shacey

Role Director

Type	Security	Shares	Price	Value
Disposition	Common Stock	16,406	$0.00	--
Disposition	Common Stock	5,398	$0.00	--
Disposition	Common Stock	7,095	$0.00	--

Holdings After Transaction: Common Stock — 5,398 shares (Direct); Common Stock — 0 shares (Indirect, By grantor retained annuity trust)

Footnotes (1)

1. On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration"). At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Petrovic Shacey

(Last) (First) (Middle)

C/O EXACT SCIENCES CORP.

5505 ENDEAVOR LANE

(Street)

MADISON WISCONSIN 53719

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EXACT SCIENCES CORP [ EXAS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/23/2026		D		16,406	D	(1)	5,398	D
Common Stock	03/23/2026		D		5,398	D	(2)	0	D
Common Stock	03/23/2026		D		7,095	D	(1)	0	I	By grantor retained annuity trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").

2. At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.

	/s/ Shacey Petrovic by Mark Busch, attorney-in- fact	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Exact Sciences (EXAS) director Shacey Petrovic report?

Shacey Petrovic reported issuer dispositions of all her Exact Sciences common stock. The Form 4 lists 16,406 and 5,398 directly held shares and 7,095 indirectly held shares, all converted in connection with the Abbott Laboratories merger.

How much cash did Exact Sciences (EXAS) shareholders receive in the Abbott merger?

Each Exact Sciences common share was converted into the right to receive $105.00 in cash. This fixed merger consideration was paid without interest to all issued and outstanding shares at the effective time, subject to the terms of the merger agreement.

What happened to Shacey Petrovic’s restricted Exact Sciences (EXAS) stock?

At the merger’s effective time, each share of Exact Sciences restricted stock became fully vested, then was cancelled and converted into the right to receive the $105.00 per share cash merger consideration, reduced only by any required tax withholding obligations.

Did the Form 4 for Exact Sciences (EXAS) include indirect holdings for Shacey Petrovic?

Yes. The filing shows 7,095 Exact Sciences common shares held indirectly through a grantor retained annuity trust. These indirect shares were also disposed of to the issuer and converted into the same $105.00-per-share cash merger consideration as other shares.

Does Shacey Petrovic hold any Exact Sciences (EXAS) shares after the Abbott merger?

No. The Form 4 indicates that following the reported transactions, Shacey Petrovic’s direct Exact Sciences common stock holdings were reduced to zero, reflecting that all reported direct and indirect shares were converted into cash in the Abbott Laboratories merger.